Navigation Links
Kensey Nash to Participate in the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum Conference
Date:3/13/2009

EXTON, Pa., March 13 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) is scheduled to present at the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum at The Grand Hyatt in New York City on Tuesday, March 24, 2009.

Joseph W. Kaufmann, Kensey Nash's CEO, will deliver the Company's presentation, beginning at approximately 11:35 a.m. (ET). The presentation materials will be available on the company's website (www.kenseynash.com) beginning at 11:35 a.m. (ET) on Tuesday, March 24, 2009.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Kensey Nash Announces Appointment of Chief Financial Officer
2. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
3. Kensey Nash Announces Director Resignation
4. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
5. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
6. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
7. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
8. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
9. Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
10. Corrected Press Release: Kensey Nash to Present at the Bank of America 2008 Health Care Conference
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... Senators and Congressmen in Competitive R...Health Care Vote , Washin... congressmen running for re-election next year in ...harlie Cook, may come to regret voting for House S...rding to a breaking Zogby International/ O’L...
(Date:11/20/2009)...N-SALEM, N.C., Nov. 20 ...ion to redefine what it means to be "happy" during...r with a specialty in family counseling and chair ...versity, Gladding says research shows that it is t...s and even depression during the holidays. ,, T...
(Date:11/20/2009)...sure readings in children with chronic kidney dise... doctor,s office visits increasing a child,s risk... from Johns Hopkins Children,s Center and other in...e in the Journal of American Society of Nephrology...ements obtained during regular doctor visits to re...
(Date:11/20/2009)...nds more severe cases than with seasonal flu , ...dian researchers are reporting that children with ...H1N1 flu than seasonal flu. , "Asthma has been ...ion with pandemic H1N1 influenza, present in 21 pe...Dr. Upton Allen and fellow researchers from the Ho...
(Date:11/20/2009)...NTAIN VIEW, Calif., Nov. 20 /PRNewswire-FirstCall/...ider of system solutions to acute healthcare facil... the 21st Annual Piper Jaffray Healthcare Confere... ,, Omnicell Speakers: Randall A. Lipps, foun...ice president & CFO ,, Date: Tuesday, Dec...
Breaking Medicine News(10 mins):Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Omnicell to Present at Piper Jaffray Healthcare Conference 2
...Services, Inc. (NYSE: WST ) today announced that...xecutive Officer, and William Federici, Chief Fina...Global Specialty Pharmaceuticals Conference at 9:0... Company,s website at www.westpharma.com . , ,...
...ew report that warns of potential liver damage fro...s of natural pain relief products are picking up s...commending stronger warnings and dose limits for d... several years now, which has led to new natural a...
...nd display whilst visiting loved ones in hospital ...ew research released by The Co-operative ISA,s. , ... deals, with 1 in 6 (17 per cent) people citing fe...efusing to pay. , , Having to pay to spend a penn...
... the National Institutes of Health (NIH), Elias A....of Trustees. Dr. Zerhouni, who directed the NIH fr...his first meeting as a board member on May 8th in ...erience and expertise that will be of great value ...
...n,t short-lived, new study shows , , FRIDA...sting your mood, exercise is the gift that keeps o...act, the feel-good afterglow a workout brings may ... can last up to 12 hours," concluded study lead re...
...y (NYSE: LLY ) announced today that the European... Products for Human Use (CHMP) has issued a positi...r injection) as monotherapy for the maintenance tr...isease has not progressed immediately following pl...
Other Medicine News:Health News:Buster Brands Launches Natural Alternatives to Acetaminophen Pain Killers 2Health News:Hospital Car Parking Fees Top the List of Life's Biggest Injustices 2Health News:Former NIH Head Joins Mayo Clinic Trustees 2Health News:Post-Exercise 'Glow' May Last 12 Hours 2Health News:Post-Exercise 'Glow' May Last 12 Hours 3Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 2Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 3Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 4Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 5Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 6Health News:ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer 7
(Date:11/20/2009)..., MINNEAPOLIS, Nov. 20 B...sults for its first quarter ended September 30, 20...uted share, on revenues of $3,263,000. This compa...ted share, on revenues of $3,168,000 for the first...st quarter results, Biotel President and CEO Steve...
(Date:11/20/2009)..., PRINCETON, N.J., Nov. 20 /PRNewswire-FirstCal...Soligenix or the Company), formerly known as DOR B..., announced today that it has formed a consortium ...x(TM) and other rapidly acting vaccines. Soligenix...nstitute of Allergy and Infectious Diseases (NIAID...
(Date:11/19/2009)..., TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/...e pharmaceutical ingredients (APIs), announced tha...ound Safety Certification from,SafeBridge(R) Consu...,s,competency and proficiency in the safe handling...), and applies to specific laboratories and,produc...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Doctors Efforts to Fight Childhood Obesity Not Working 56256 1Nurses and Retirement Security 3A A Looming Crisis 3F 56253 1Nurses and Retirement Security 3A A Looming Crisis 3F 56253 2Nurses and Retirement Security 3A A Looming Crisis 3F 56253 3Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 13861 1Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 13861 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 13861 3
...(Nasdaq: CRGN ), a clinical-stage biopharmaceutic... (Copenhagen Stock Exchange: TOPO) announced,today...rom the Phase II,study of belinostat for T-cell ly...ostat on pediatric leukemia cell lines, will be pr... (ASH) 49th Annual Meeting in,Atlanta, GA, on Mond...
...VELCADE in front-line, multiple myeloma to be fe... Society of Hematology (ASH) Annual Meeting...euticals, Inc. (Nasdaq: MLNM ) today announced th...E clinical studies are scheduled to be,featured at...December 8-11,2007. The data will highlight the si...
Other Medicine Technology:CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 2CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 3CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 2New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 4New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 6
Maverick Over-The-Wire 25 mm Catheter
Maverick Over-The-Wire 15 mm Catheter
...ated Phoroptor features lighted dials to make it e... the darkened setting of the exam room. Put away y...the entire process. The Illuminated Phoroptor feat...xis scales that are easier than ever to see. The I...
Illuminated PHOROPTOR Refracting Instrument - Plus Cylinder Black
Medicine Products: